Download steht ein Titel. Dieser Titel kann auch drei Zeilen

Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm
(7.RP) für Forschung und Entwicklung
Ylva Huber
Bereich Europäische und Internationale Programme
FFG – Österreichische Forschungsförderungsgesellschaft
Inhalt
• Generelle Gesichtspunkte des 7. EURahmenprogramms
• Health“ und „Food, Agriculture and Fisheries, and
Biotechnology“ in der 1. Ausschreibung
• Das Programm „IDEAS“
Inhalt
• Generelle Gesichtspunkte des 7. EURahmenprogramms
• „Health“ und „Food, Agriculture and Fisheries, and
Biotechnology“ in der 1. Ausschreibung
• Das Programm „IDEAS“
Budget FP7: für „Common Approach“
Cooperation
Health
Biotech, Food, Agriculture
Information Society
Nanomaterials Production
Energy
Environment
Transport
Socio-economic Research
Security and Space
Ideas
People
Capacities
32.315
6.000
1.935
9.120
3.505
2.300
1.900
4.195
610
2.750
7.460
4.728
4.267
Total: 50.521 billion EUR
(incl. Joint Research Centre 1,7 Mrd)
Instrumente im 7. RP
7. EU-Rahmenprogramm
6. EU-Rahmenprogramm
Verbundprojekte („Collaborative
Projects)
Exzellenznetze (NoE)
Integrierte Projekte (IP)
Gezielte Forschungsprojekte (STREPs)
Exzellenznetze (NoE)
Koordinierungsmaßnahmen (CA)
Koordinierungsmaßnahmen (CA)
Unterstützungsmaßnahmen (SSA)
Unterstützungsmaßnahmen (SSA)
Unterstützung für Ausbildung und
Karriereentwicklung (Marie-Curie)
Unterstützung für Ausbildung und
Karriereentwicklung (Marie-Curie)
Einzelprojekte im ERC (Programm
Ideas)
KMU spezifische Maßnahmen
KMU spezifische Maßnahmen
Artikel 169
Artikel 169
ERA-NET und ERA-NET PLUS
ERA-NET
Gemeinsame Technologieinitiativen (JTI)
Förderhöhen im 7. RP
Abschaffung der Kostenmodelle
• Forschung und Entwicklung: Förderung bis zu 75%
- Universitäten
- Forschungsorganisationen
- Öffentliche Einrichtungen
- KMU
• Unternehmen: 50%
• Demonstration: bis zu 50%
• Grundlagenforschung: bis zu 100%
• Specific Support Actions und Coordination Actions: bis zu 100%
• Pauschalen für indirekte Kosten sind möglich
Vereinfachung der Abläufe
Technologieplattformen und
Gemeinsame Technologieinitiativen
• Mobilisierung europäischer Ressourcen im Bereich Forschung,
technologische Entwicklung und Innovation durch Zusammenbringen aller
Akteure eines definierten Forschungsbereiches (Industrie, KMU,
Universitäten, Endverbraucher)
• Industriegetrieben
• Gemeinsame Definition und Erstellung einer strategischen
Forschungsagenda (mittel- bis langfristig)
= Input zur Entwicklung der thematischen Programme im 7. RP
• Einige wenige werden als Gemeinsame Technologieinitiativen (Joint
Technology Initiatives) etabliert
• Neuer Weg zur Realisierung von public-private partnerships auf EUEbene mit definierter rechtlicher Struktur
Inhalt
• Generelle Gesichtspunkte des 7. EURahmenprogramms
• Ausschreibungsthemen zu „Health“ und
„Biotechnologies, Agriculture, Food and Fisheries“
• Das Programm „IDEAS“
• Nächste Schritte
Thema 1- Gesundheit
(6.050 Mio. Euro)
Ziele:
 Verbesserung der Gesundheit der europäischen Bevölkerung
 Stärkung der europ. Industrie/Firmen
im Bereich Gesundheit
 Blick auf globale Gesundheitsfragen
(z.B. Epidemien
Schwerpunkte:
 Translationale Forschung (Grundlagenforschung  klinische
Anwendung)
 Neue Therapien (Entwicklung und Validierung)
 Methoden zur Gesundheitsförderung, Krankheitsprävention
 Diagnostische Instrumente und medizinische Technologien
 Effiziente Gesundheitssysteme
Theme 1: HEALTH
(6.000 Mio. €)
Activities
1
Biotechnology, generic tools and technologies for human
health
2
Translating research for human health
3
Optimising the delivery of health care to European Citizens
4
Other Actions across the Health Theme
1
Biotechnology, generic tools and technologies for human
health (1)
High-throughput research




Unifying human and model organism genetic variation databases
Temporal and spatial proteomics to study biological processes relevant to
human health
Groundbreaking techniques for DNA sequencing and genotyping
2. Call:
SME-driven collaborative research projects for developing tools and technologies
for high-throughput research
Detection, Diagnosis and Monitoring






Development of a hybrid imaging system
Novel optical methodologies for detection, diagnosis and monitoring of disease or
disease-related processes
Novel targeted imaging probes for early in vivo diagnosis and/or evaluation of
response to therapy
In vivo image-guidance for cell therapy
2. Call :
Standardisation and improvement of pre-analytical procedures for in vitro
diagnostics
High throughput molecular diagnostics in individual patients for genetic
diseases with heterogeneous clinical presentation
1
Biotechnology, generic tools and technologies for human
health (2)
Predicting suitability, safety and efficacy of therapies
Thema zum Großteil durch Innovative Medicines Initiative (IMI) abgedeckt!





Novel alternative testing strategies for use in pharmaceutical discovery and
development
Bottlenecks in reduction, refinement and replacement of animal testing in
pharmaceutical discovery and development
Promotion, development, validation, acceptance and implementation of QSARs
(quantitative structure-activity relationship) for toxicology
Alternative testing strategies for the assessment of the toxicological profile of
nanoparticles used in medical diagnostics
In silico modelling for ADMET outcomes
1
Biotechnology, generic tools and technologies for human
health (3)
Innovative therapeutic approaches and interventions



Development and production of new generation antibodies
Innovative approaches for the development of vaccines for young children
Immunotherapy of human food allergies
2.Call:





Development of emerging gene therapy tools and technologies for clinical
application
Stem cell lines for cell-based therapies.
Development of stem cell culture conditions.
Stem cells for kidney regeneration.
Adding value to EU stem cell therapy research: scientific communication and
future perspectives.
Translating research for human health (1)
2
2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY
Large-scale data gathering







Networking biobanking initiatives across Europe: developing standards and
norms for existing and future human sample biobanks
Molecular epidemiological studies in existing well characterised European
(and/or other) population cohorts
Comparative studies of genetic variation in humans: towards a reference
population in Europe
Characterisation and variability of the microbial communities in the Human
Body
Structure-function analysis of membrane-transporters and channels for the
identification of potential drug target sites
High throughput analysis of lipids and lipid-protein interactions
Genome-wide association studies in mammalian non-rodent models for the
identification of genes relevant to human health and disease
Translating research for human health (2)
2
2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES
LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY
Systems biology




A system approach to eukaryotic unicellular organism biology
Modelling of T-cell activation
Fundamental approaches to stem cell differentiation
Developing an integrated in vitro, in vivo and systems biology modelling approach to
understanding apoptosis in the context of health and disease
2. call:



Multidisciplinary fundamental genomics and molecular biology approaches to study
basic biological processes relevant to health and diseases
Coordination and Support Actions in large-scale data gathering and systems biology
Traditional Chinese Medicine in post-genomic era. Specific International
Cooperation Action. Targeted region: China.
2
Translating research for human health (3)
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN
DEVELOPMENT AND AGEING
Brain and related diseases






Stroke and mechanisms underlying ischemic brain damage
Coding in neuronal assemblies
Neurobiology of anxiety disorders
Memory loss: underlying mechanisms and therapy
From basic spinal mechanisms to spinal cord disease and trauma.
Neuron-glia interactions in health and disease
2. Call:




Restorative approaches for therapy of neurodegenerative diseases.
From mood disorders to experimental models.
Neuronal mechanisms of vision and related diseases.
Childhood and adolescent mental disorders. Specific International Cooperation
Action. Target regions: Eastern Europe and Central Asia and Western Balkans.
2
Translating research for human health (4)
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN
DEVELOPMENT AND AGEING
Human Development and Ageing





Novel approaches to reconstitute normal immune function at old age.
Termination of developmental processes and their reactivation in adult life
Biomarkers of ageing.
Increasing the participation of elderly in clinical trials.
Research on human development and/or healthy ageing across the EU
2
Translating research for human health (5)
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
Anti-microbial drug resistance including fungal pathogens
2. Call:

Novel targets for drugs against Gram negative bacteria.

Host-pathogen interactions in infections by Streptococcus pneumoniae.

An integrated platform for development and clinical evaluation of point-of-care
diagnostic devices for microbial detection, antibiotic susceptibility determination
and biomarkers

Molecular epidemiology to control nosocomial and community spreading of highly
virulent multi-drug resistant strains of bacterial pathogens.

Health and economic cost of antimicrobial resistance.

Conference on genetic and biochemical tools for postgenomic physiological analysis
of Staphylococcus, in particular MRSA.
Translating research for human health (6)
2
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
HIV, AIDS, malaria and tuberculosis

HIV/AIDS Drug Discovery and Preclinical Development
Highly innovative approaches for research into host-pathogen interaction in tuberculosis
Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria and
tuberculosis and of latent tuberculosis infection (LTBI).
Addressing knowledge gaps in pregnancy malaria.
New HIV Vaccines inducing broadly-reactive neutralising antibodies.

2. Call:

Network on HIV and anti-HIV drug resistance
HIV and Hepatitis co-infection
Blocking the transmission of malaria: the mosquito vector target.
European network for study and clinical management of TB drug resistance.
Support platform for the development of PRD vaccines
Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and European
partners. (SICA, Targeted Region: India)
Coordination of European research activities with global initiatives, including Public-PrivatePartnerships (SICA; Targeted Regions: ICPC).
Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious
diseases (SICA; Targeted Regions: ICPC).











2
Translating research for human health (7)
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:
TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH
Potentially new and re-emerging epidemics








Development of broadly protective influenza vaccine candidates.
Identifying immunological mechanisms of protection for influenza vaccines
Standardisation of immunological assays including surrogate markers for evaluation of new
influenza vaccines in clinical trials
Innovative point-of-care diagnostic tests for influenza.
Development of additional treatment strategies for patients suffering from highly pathogenic
influenza.
Development of pandemic influenza containment and mitigation strategies.
Supporting highly innovative inter-disciplinary research on influenza.
Influenza research in collaboration with Asian partners. (SICA, Targeted regions: Asia)
2. Call:


Strengthening research on prediction, identification, modelling and surveillance of newly
emerging infectious diseases in humans.
Definition of research needs and priorities in Europe in the area of Emerging Infectious
Epidemics.
2
Translating research for human health (8)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Cancer
•
•
•
•
•
•
•
•
Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel
diagnosis and therapy strategies.
Translating clinical ’omics’-technology (genomics, proteomics, metabolomics) into innovative
cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer
patients.
Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer.
Novel cancer screening methods.
Optimising research on end of life care of cancer patients.
Understanding and fighting metastasis.
Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy
Developing high-throughput bioassays and models for human cancers in lower species.
2. Call:
•
Innovative combination clinical trials for multimodal cancer therapy.
•
Role of inflammation in tumour initiation and progression.
•
Epidemiology of gene-environment interactions involved in carcinogenesis.
•
Translating the hypoxic tumour microenvironment.
•
ERA-NET on optimisation of the use of cancer registries for cancer research purposes
•
Studying cancer aetiology in Latin America. (SICA)
2
Translating research for human health 9)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Cardiovascular Disease



Molecular basis of the inflammatory response and associated vascular remodelling in
arteriosclerosis.
Vascular remodelling in aneurysmal disease.
Combating stroke.
2. Call:

Congenital pathologies affecting the heart.

Cell therapies for the treatment of heart ischemia.

Organ imaging in CVD.

Integrating pharmacogenomic approaches into the treatment of CVD.
2
Translating research for human health 10)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Diabetes and Obesity

Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention.
Combined forms of diabetes in children.

Insulin resistance as a key factor in the development of diabetes and metabolic syndrome.

Pathophysiological mechanisms related to excess fat.

A road-map for diabetes research.

2. Call:




Nutritional signals and the development of new diabetes/obesity therapeutic agents.
Markers and treatment for diabetic neuropathy complications.
Geno- and phenotypical differentiation of type 2 subjects and monogenic subjects.
Use of beta cell imaging in diabetes mellitus.
2
Translating research for human health 11)
TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
Rare Diseases


Natural course and pathophysiology of rare diseases.
Research capacity-building in the field of rare diseases.
Other Chronic Diseases
Osteoarthritis.

Inflammatory bowel disease.

Osteoporosis: signalling pathways in bone formation and homeostasis.

Genetic factors of Osteoporosis.

Intervertebral disc degeneration: prevention and repair.

Innovative concepts in chronic obstructive pulmonary disease pathogenesis (COPD).

Hearing impairment and degeneration.

Impairment of touch and proprioception at old age.

Visual impairment and degeneration.
2. Call:

Understanding and combating age-related muscle weakness.

Translational research aiming for a treatment of urinary incontinence.

Early processes in the pathogenesis of chronic inflammatory diseases.

3
Optimising the delivery of health care to European Citizens (1)
Translating clinical research into clinical practice including better use of
medicines, and appropriate use of behavioural and organisational
interventions and health therapies and technologies
2.call:







Implementation of research into healthcare practice
Self-medication and patient safety
Patient Safety Research Network
Improving clinical decision making
Better use of medicines.
Continuity of clinical care.
Patient self-management of chronic disease.
Quality, solidarity and sustainability of health systems
2.call:








Evaluation of disease management programmes
Health systems and long term care of the elderly
Mobility of health professionals
Health care human resource planning in nursing.
Clinician working time and patient safety.
Health outcome measures and population ageing.
Trends of population health
European system of Diagnosis-related groups (DRG)
3
Optimising the delivery of health care to European Citizens (2)
Enhanced health promotion and disease prevention
2.call:





Promoting healthy behaviour in children and adolescents
Interventions addressing the gradient of health inequalities
Public health interventions addressing the abuse of alcohol.
Evaluation of suicide prevention strategies across and within European countries.
Improve vaccination coverage
Horizontal Coordination and Support Actions across “Optimising the Delivery
of Health Care to European Citizens
2.call:








Disease networks of centres of reference.
Effectiveness of health investments.
Patient mobility and access to information.
Brokering research into policy.
A road-map for ageing research.
Health Services Research conference
Mental health research conference.
Public Health intervention research conference
3
Optimising the delivery of health care to European Citizens (3)
Specific International Cooperation Actions for Health System Research
2.call:

Epidemiological investigations into long-term trends of population health as
consequence of socio-economic transitions, including life-style induced
health problems. SICA (Mediterranean Partner countries, Russia, Eastern
European and Central Asia)

Universal and equitable access to health care and health financing. SICA
(MCP, ACP, Asia and Latin America)

Health care intervention research – optimising hospital care. SICA (Western
Balkans.)

Health care intervention research – improving pre-natal and maternal care.
SICA (ACP and Mediterranean Partner Countries)
4
Other Actions across the Health Theme
Coordination and Support Actions across the Theme
•
•
•
•
•
Reinforcing the network of National Contact Points (NCP) for the Seventh Framework
Programme under Health Theme by promoting transnational co-operation.)
Promoting participation of high-technology research intensive SMEs, operating in the
biomedical engineering and other medical technology sectors´relevant to Health Theme.
Assessment and valorisation of project outcome for hightechnology and research intensive
SME participating to Framework Programmes of Research in the healthcare sector.
Science communication actions.
Initiatives to foster dialogue and debate on health research issues of interest to the
public.
•
Studies on the impact of EU legislation on health research and related developments and
applications.
2.call:
•
Promotion and facilitation of international cooperation in areas relevant to the objectives of
this theme. (SICA, ICPC)
Responding to EU policy needs (2.call)

Paediatric medicinal products, Drug safety research, Living and work conditions,
Health statistics, Tobacco Control
Example „Innovative Medicines“ en route to a „Joint Technology Initiative“
 Accelerated Development of safe and more effective medicines
 Revitalization of the the biopharmaceutical research and development (R&D)
environment for Europe to become more competitive
 Improving the collaboration between all relevant actors from public and
private organisations (public-private partnerships)

Draft and Implementation of a European Research Agenda:
Second version of the Strategic Research Agenda published recently
 First Calls
expected for end of 2007/beginning of 2008
 http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed
 http://rp7.ffg.at/RP7.aspx_param_target_is_116120.v.aspx
« Innovative Medicines »
2. version of the « Strategic Research Agenda »:
4 main topics:

Safety:
Early safety evaluation and risk assessment, creation of a European Centre
for Drug Safety

Efficacy:
Predictive pharmacology, biomarker identification and validation, patient
recruitment and risk assessment

Knowledge Management:
New technologies to control and analyse enormous quantities of information in
an integrative and predictive way

Education and Training:
Bridge gaps in expertise required to strengthen the biopharmaceutical R&D
process, creation of a European Medicines Research Academy
Technologieplattform
« Innovative Medicines »

Contact in Austria:
Univ. Prof. Dr. Hans Georg Eichler,
Vice Rector of the Medical University in Vienna
[email protected]
Thema 2 - Lebensmittel, Landwirtschaft,
Fischerei und Biotechnologie
(1.935 Mio Euro)
Ziel:
 Aufbau einer “wissensgestützten Bio-Wirtschaft”






Schwerpunkte:
Sicherere, gesündere und hochwertigere Lebensmittel
Tierschutz
Nachhaltige Produktion und Verwendung nachwachsender BioRohstoffe
Epizoonosen und Zoonosen
Lebensmittelbedingte Dysfunktionen
Nachhaltigkeit und Sicherheit der landwirtschaftlichen Erzeugung
und der Fischerei
Thema 2 - Lebensmittel, Landwirtschaft,
Fischerei und Biotechnologie
1
Nachhaltige Erzeugung und Bewirtschaftung der biologischen
Ressourcen aus Böden, Wäldern und der aquatischen Umwelt
2
“Vom Tisch zum Bauernhof”: Lebensmittel, Gesundheit
und Wohlergehen
3
Biowissenschaften und Biotechnologie im Dienste
nachhaltiger Non-food-Erzeugnisse und Verfahren
1
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Nachhaltige Erzeugung und Bewirtschaftung der biologischen
Ressourcen aus Böden, Wäldern und der aquatischen Umwelt
Development of new tools and processes to support R&D in crop plants: molecular breeding
Mining genomics information of farm animals to generate new information on the genetic basis
of phenotypes important to sustainable animal production
Development of genetic systems for crop improvement through a systems biology approach
Development of technologies and tools for the exploitation of livestock genome
Using new technologies to identify (re-)emerging pathogens from wildlife reservoirs
Annual food crops with improved tolerance to multiple abiotic stresses
Genomics for cereal improvement for food, feed and non-food uses
Development of more efficient risk analysis techniques for pests and pathogens of
phytosanitary concern
Reducing the need for external inputs in high-value protected horticultural and ornamental
crops
Developing new methods for valuing and marketing of currently non-marketable forest goods
and services
Coordination of Agricultural Research in the Mediterranean
Reduction of N excretion in ruminants
From capture based to self-sustained aquaculture
Breeding tools for improved livestock products
The farm of tomorrow
GMO cost-effective and crop-specific co-existence measures
(...)
2
•
•
•
•
•
•
•
•
•
“Vom Tisch zum Bauernhof”: Lebensmittel, Gesundheit
und Wohlergehen
Smart control for improved food and feed technologies (Large collaborative
project)
Assessment and improvement of existing food and feed technologies (Small
collaborative project)
Nano-devices for quality assurance, food safety and product properties(Small
collaborative projects)
Exposure to food additives, flavourings, and migrants coming from food contact
materials – dietary intake models (Large collaborative project)
Innovative and safe packaging (Small collaborative project)
Post Market Monitoring of the effect of GM food and feed on human and animal
health (Small collaborative project)
Converging technologies and their potential for the food area (Small
collaborative project)
Detecting contaminants in the Food and Feed Chain
(…)
3
•
•
•
•
•
•
•
•
•
Biowissenschaften und Biotechnologie im Dienste
nachhaltiger Non-food-Erzeugnisse und Verfahren
ENGERGY PLANTS – Novel plants for energy production (Small collaborative
project)
GREEN OIL: Plants providing oils for the future (Large collaborative project)
BIO-VET-Pharming: Plant made recombinant pharmaceuticals for animals
(Network of Excellence)
FOREST PRODUCTS – New forest based products and processes (Large
collaborative project)
GREEN FACTORY – The expression and accumulation of valuable industrial
compounds in plants (Large collaborative project)
Improved Microbes – Metabolic engineering and modelling (Coordination and
Support Action)
IMPROVED MICROBES for the Environment – Microbial gene expression under
conditions of stress (Large collaborative project)
ANIMAL BY PRODUCTS - Nove methods of treatment of animal by products
for the production of substances with biologically valuable functional
properties (Small collaborative project)
And many more….
EuropäischeTechnologie-Plattformen
im Bereich Lebensmittel, Landwirtschaft
und Biotechnologie
Plants for the Future:
http://www.epsoweb.org/Catalog/TP/index.htm
Food for Life:
http://etp.ciaa.be/asp/home/welcome.asp
Global Animal Health:
http://www.ifahsec.org/Europe/EUPlatform/Platform.htm
Farm Animal Breeding and Reproduction:
http://www.fabretp.org/
Weitere relevante Themen der 1.
Ausschreibung aus anderen Bereichen
Information and Communication Technologies:
Objective ICT-2007.5.3: Virtual Physiological Human
Nanosciences, Nanotechnologies, Materials and new Production
Technologies:
„Creation of a critical and commented database on the health,
safety and environmental impact of nanoparticles“
„Process intensification in chemicals production“
„Substantial innovation in the European medical industry: development of
nanotechnology-based systems for in-vivo diagnosis and therapy (in
Coordination with topic HEALTH-2007-2.4.1-7 and HEALTH-2007-1.2-3 in
Theme 1 "Health")
Inhalt
• Generelle Gesichtspunkte des 7. EURahmenprogramms
• Health“ und „Food, Agriculture and Fisheries, and
Biotechnology“ in der 1. Ausschreibung
• Das Programm „IDEAS“
23. November 2006
Medizinische Universität Graz
Das Programm IDEAS – ein Überblick
Ziele des Spezifischen Programms IDEAS
Rolle des European Research Council (ERC)
Förderlinien
Page 41/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
Worum geht es beim Spezifischen Programm IDEAS?
Grundlagenorientierte Spitzenforschung (Pionierforschung)
Alle Forschungsbereiche
Umsetzung durch European Research Council ERC
Page 42/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
 Forschung an den Grenzen des Wissens (Pionierforschung)
 riskant
 interdisziplinär
 schwer voraussagbar in ihrer praktischen Anwendung
 Vermeidung unzeitgemäßer Unterscheidungen:
 Grundlagenforschung - angewandte Forschung
 Wissenschaft -Technologie
 traditionelle Disziplinen
Page 43/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
Wozu Pionierforschung?
Page 44/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
Welche Rolle spielt der ERC?
Mittel des spezifischen Programms IDEAS werden für die Aktivitäten
des European Research Council (ERC) eingesetzt
 Hebelwirkung -> strukturelle Verbesserung im Europäischen
Forschungssystem
 Erhöhung der Exzellenz, Dynamik und Kreativität im Bereich
Grundlagenforschung
 Stärkung vorhandener Potentiale “an den Grenzen des Wissens”
 Einziges Evaluierungskriterium: EXZELLENZ
Page 45/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC – Struktur und Organisation
 Forschungsrat (Scientific Council)
 Unabhängige Festlegung der ERC-Strategie, wissenschaftlicher
Zielsetzungen, Abwicklung
 Unterstützt durch Agentur (Dedicated Implementation Structure)
 Agentur (Dedicated Implementation Structure)
 Praktische Implementierung und operatives Management
 Europäische Kommission
 stellt die finanziellen Mittel zur Verfügung
 sorgt für Autonomie des ERC
Page 46/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC - Wissenschaftliche Schwerpunkte
 Physikalische und technische Wissenschaften
 Lebenswissenschaften
 Sozial- und Geisteswissenschaften
Page 47/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC – Panels
 20 Scientific Panels
 20 Panel-Vorsitzende
(International anerkannte WissenschafterInnen und
ForscherInnen)
 200 Panel-Mitglieder
(WissenschafterInnen und ForscherInnen aus den jeweiligen
Fachgebieten)
 1000 - 2000 GutacherInnen
(Consultation letter an Europäische Forschungsorganisationen)
Page 48/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
Welche Förderschienen gibt es?
 ERC Starting Independent Researchers Grants
(ERC Starting Grant)
 ERC Advanced Investigator Grants
(ERC Advanced Grant)
Page 49/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC Starting Grants
Unterstützt werden exzellente Forschende aller Nationalitäten, die ihr erstes
selbständiges ForscherInnen-Team in Europa etablieren wollen. Der Weg in
die Unabhängigkeit wird unterstützt
 Ausschreibung: 22. Dezember 2006
 Einreichfrist: April 2007 für die erste Stufe
ERC Advanced Grants
Für exzellente ForscherInnen und WissenschafterInnen, die bereits eine
gewisse Unabhängigkeit erlangt haben -> als Folgeprogramm des “Starting
Grants” zu verstehen
 Ausschreibung: Sommer 2007
 Einreichfrist: Anfang 2008
Page 50/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC Starting Grants
 Projektvorschläge werden von einzelnem/r Forscher/in (“Principal
investigator”) eingereicht.
 Durchführung der Projekte: transnationale oder nationale Teams
 Teamleiter: jede Nationalität
befindet sich in einer Forschungseinrichtung in
Europa (EU25, Kandidatenländer, assoziierte
Länder)
 Teammitglieder: jede Nationalität
 Verträge werden zwischen dem ERC und der Gasteinrichtung des
Teamleiters abgeschlossen, die für das unabhängige Arbeiten des
Teams garantieren muß.
Page 51/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC Starting Grants - wer reicht ein?
TeamleiterIn (“Principal Investigator”)
 Über 2, weniger als 8 Jahre Forschungserfahrung nach Abschluß
des Doktorats.
 Teamleiter darf nur in einem Starting Grant – Projekt tätig sein.
 Keine Beschränkungen bei der Wahl der Projektinhalte.
 Es muß das erste unabhängige Team sein.
 Fähigkeit, eigenes Team zu etablieren.
Page 52/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC Starting Grants - Evaluierungskriterien
1. Principal Investigator: Potential to become a world class research
leader
 Quality of research output
 Intellectual capacity and creativity
2. Quality of the proposed research project
 Ground-breaking nature of the research
 Potential impact
 Methodology
3. Research Environment
 Transition to independence
 Host institution (normally applicant legal entity)
 Participation of other legal entities
Page 53/45
Y.Huber / FFG-EIP
23. November 2006
Medizinische Universität Graz
ERC – weitere Information
Kontakt:
Ralf König
[email protected]
+43 (0)57755 - 4601
http://rp7.ffg.at/erc
 http://rp7.ffg.at/erc
 http://erc.europa.eu
 http://cordis.europa.eu/fp7/ideas.htm
 http://ec.europa.eu/research/future/index_en.cfm
Page 54/45
Y.Huber / FFG-EIP
Vielen Dank für Ihre Aufmerksamkeit
&
viel Erfolg für Ihre Projekte
im 7. Rahmenprogramm!